NR3C2 and hydrops fetalis: In the pivotal RALES and EMPHASIS-HF trials, spironolactone and eplerenone reduced the incidence of all-cause mortality and hospitalization in HFrEF patients [76, 77], providing unequivocal evidence to support the inclusion of steroidal MR antagonists in guideline-directed medical therapy [5].